Is Medicamen Organ. overvalued or undervalued?

As of 10 October 2025, the valuation grade for Medicamen Organ. has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios include a PE ratio of 12.83, an EV to EBITDA of 9.15, and a ROCE of 12.71%. When compared to peers, Medicamen Organ. stands out with a significantly lower PE ratio than Sun Pharma. Inds., which has a PE of 34.96, and is also less favorable than Cipla, which boasts a PE of 23.39. Despite its recent stock performance showing a 7.82% return over the past week compared to a 1.57% return for the Sensex, the overall year-to-date return of -33.49% highlights the challenges the company faces in maintaining investor confidence.